Short answer: RASolute 302 showed a substantial overall-survival benefit for daraxonrasib in previously treated metastatic pancreatic cancer, and the FDA approved the drug on August 26, 2026. The approved indication also covers adults who are not candidates for multiagent systemic therapy, an alternative group that public descriptions of the pivotal trial do not establish as a separately randomized population. That distinction does not mean the approval lacks trial support overall. Nor does the available evidence establish that RVMD shares are “priced for” the label—or that a hold rating is warranted: a current share price and a valuation model are needed to assess that claim.
What did RASolute 302 actually test?
RASolute 302 was an international, open-label, randomized Phase 3 trial comparing daraxonrasib with chemotherapy chosen by the investigator. It enrolled patients with metastatic pancreatic ductal adenocarcinoma whose disease had progressed after one prior line of systemic therapy, according to the FDA’s description of the efficacy study.
In the overall trial population, median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy. The FDA summary reports a hazard ratio of 0.40 (95% confidence interval 0.30–0.53; p<0.0001). The NEJM report gives the same median survival figures and hazard ratio for the overall population, with P<0.001.
The trial also reported a distinct RAS G12 population: median overall survival was 13.2 months with daraxonrasib and 6.6 months with chemotherapy, with a hazard ratio of 0.40. Do not substitute that subgroup’s chemotherapy result for the overall-population figure of 6.7 months.
#1 Best Overall
These are trial medians, not a prediction of how long an individual patient will live. The comparison was against investigator-choice chemotherapy in this study; it does not establish superiority over every possible treatment regimen or in every treatment setting.
How does the FDA indication compare with the trial population?
The FDA approved daraxonrasib, marketed in the United States as RASONQUE, on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The FDA identifies RASolute 302 as the efficacy study and describes it as enrolling patients whose disease progressed after one prior line of systemic therapy.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
| Question | What the available description establishes |
|---|---|
| Previously treated metastatic disease | RASolute 302 was randomized evidence in patients with metastatic pancreatic cancer after prior systemic therapy; the FDA describes one prior line. |
| Patients not candidates for multiagent systemic therapy | This is an alternative clause in the FDA-approved indication. The public trial descriptions reviewed here do not establish it as a separately randomized population. |
| Does the distinction mean the entire approval lacks trial evidence? | No. The pivotal trial provides randomized evidence in previously treated metastatic disease. The narrower question is whether the alternative label wording was independently tested as a distinct population. |
A label’s wording and a trial’s reported enrollment criteria are not interchangeable. The evidence supports the drug’s studied population; the public descriptions cited here do not show a separate randomized test of the “not candidates” group. That is a boundary on what can be concluded from the reported trial, not proof that FDA approved an unsupported medicine.
What does the approval establish—and what remains a separate question?
The approval establishes a current U.S. regulatory indication for the defined metastatic pancreatic adenocarcinoma population. It does not establish that daraxonrasib works in earlier treatment lines, after surgery, or in lung cancer; those questions are being evaluated in different studies.
The FDA efficacy summary and the peer-reviewed NEJM report are the relevant primary sources for the approved indication and RASolute 302 outcomes. Revolution Medicines’ later filings describe the company’s development programs and financial position. Company plans and projections are not clinical results, and a trial’s planned enrollment or expected readout can change.
Which future programs could expand the opportunity?
Revolution Medicines’ June 2026 filing describes several Phase 3 programs. Each addresses a different treatment line, combination, mutation group, or cancer type; none inherits RASolute 302’s efficacy result simply because it includes daraxonrasib or another RAS(ON) inhibitor.
Rank #4
| Study | Program described in the June 2026 filing | What makes it distinct |
|---|---|---|
| RASolute 303 | Daraxonrasib with and without chemotherapy versus chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma (PDAC). | First-line metastatic disease rather than the previously treated setting studied in RASolute 302. |
| RASolute 304 | Adjuvant daraxonrasib after surgery and chemotherapy. | Post-surgery treatment, not metastatic disease treated after progression on a prior line. |
| RASolute 305 | Zoldonrasib with chemotherapy in first-line metastatic PDAC. | A different investigational medicine and treatment setting. |
| RASolute 309 | Daraxonrasib plus zoldonrasib in first-line RAS G12D PDAC. | A combination program focused on a specified mutation group and first-line disease. |
| RASolve 301 | Daraxonrasib versus docetaxel in previously treated RAS-mutant non-small-cell lung cancer (NSCLC). | A different cancer type and comparator. Enrollment and readout expectations in the filing are company guidance, not guaranteed dates. |
The same filing lists daraxonrasib, zoldonrasib (RMC-9805), elironrasib (RMC-6291), and RMC-5127 as clinical-stage RAS(ON) inhibitors, while also describing preclinical opportunities. Clinical-stage and preclinical candidates remain investigational; they are not additional approved medicines. Their distinct mutation targets and development stages matter when estimating how much future revenue any one program might add.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What do the company’s finances say about development capacity?
As of June 30, 2026, Revolution Medicines reported $3.9 billion in cash, cash equivalents, and marketable securities. The company said that total included proceeds from April 2026 public offerings and convertible notes, as well as a May 2026 royalty-funding tranche.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
- Second-quarter 2026 research and development expense: $394.9 million.
- Second-quarter 2026 net loss: $644.4 million, including a non-cash $151.0 million warrant fair-value charge.
- Updated full-year 2026 GAAP operating expense guidance: $2.1 billion to $2.2 billion.
Those figures show both substantial reported resources and substantial development spending. They do not, by themselves, establish how long the cash will last, what the shares are worth, or what return an investor might earn. The earlier first-quarter operating-expense guidance was superseded by the second-quarter update; the two ranges should not be treated as simultaneous current guidance.
Can the evidence support “priced for” or “hold”?
Not on its own. The clinical and company materials summarized above establish approval, trial outcomes, development programs, and financial figures, but they do not establish a current RVMD share price, market capitalization, or explicit valuation model. Without those inputs, it is not possible to verify that the market has priced in either the approved indication or broader future uses. The available evidence also cannot independently justify a hold rating.
A valuation assessment would need to make its assumptions explicit. At minimum, an investor would need to examine:
- Approved-product economics: the addressable patient population, treatment uptake, net price, duration of therapy, and commercial costs for the approved U.S. indication.
- Evidence by setting: which opportunities have randomized Phase 3 results, which are still under study, and whether the trial population matches the patients a forecast assumes will be treated.
- Development risk and timing: mutation subtype, trial design, competition, regulatory steps, and the uncertainty around company-projected enrollment or readout timing.
- Funding and dilution: spending needs, cash use, financing terms, and the potential effect of additional capital raising on existing shareholders.
- Market expectations: a dated share price and market capitalization, compared with a transparent estimate of risk-adjusted future cash flows rather than an unsupported claim that expectations are already embedded.
For an investor, the practical distinction is between a promising approved product with a defined evidence base and a broader pipeline whose value remains contingent on separate trials and eventual commercialization. Whether that profile merits buying, holding, or selling depends on the share price and the investor’s own valuation assumptions—not on the label-versus-trial distinction alone.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
